She obtained her PhD in Molecular and Cellular Biology and Biochemistry at the University of Nice–Sophia Antipolis (Prof. E. Van Obberghen lab, INSERM U145, France) in 1999. She subsequently spent more than two decades (1999–2021) conducting academic research at institutions affiliated with Cancer Research UK in London. She began her postdoctoral training in Prof. Julian Downward's laboratory at the London Research Institute and Imperial College London, where she investigated the RAS/PI3K/Akt signalling pathway in cancer. She later joined Prof. Banafshe Larijani's Cell Biophysics Laboratory at the London Research Institute, where she applied advanced FRET-FLIM quantitative imaging techniques to elucidate the molecular mechanisms underlying the interaction, structure, and function of PDK1 and Akt. In recognition of her expertise, she was invited to join the Editorial Advisory Board of the Biochemical Journal in 2011, contributing to its Signal Knowledge Environment section. In 2016, she joined Prof. Peter Parker's laboratory at the Francis Crick Institute, where she investigated an oncogenic mutation of PKCα using genetically engineered mouse models, multi-omics and biochemical approaches. Since 2021, she has served as Chief Scientific Officer at Hawk Biosystems, where she leads scientific innovation and research development, advancing technologies for the quantitative analysis of protein function in spatial proteomics.